Methyl 2-((6-chloropyridazin-4-yl)oxy)acetate

Catalog No.: 
ACFFIP180
CAS No.: 
1346691-35-7
Molecular Formula: 
C7H7ClN2O3
Molecular Weight: 
202.60
Methyl 2-((6-chloropyridazin-4-yl)oxy)acetate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$480.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameMethyl 2-((6-chloropyridazin-4-yl)oxy)acetate
IUPAC Namemethyl 2-((6-chloropyridazin-4-yl)oxy)acetate
MDL No.MFCD19704373
Molecular FormulaC7H7ClN2O3
Molecular Weight202.60
SMILESO=C(OC)COC1=CC(Cl)=NN=C1
InChI KeyPKIGUQASUGQUMZ-UHFFFAOYSA-N
Synonymmethyl 2-(6-chloropyridazin-4-yloxy)acetate
CAS No.1346691-35-7

Safety Data

Pictogram
Toxic
Signal Word
Danger
Hazard Statement(s)
H301-H311-H331
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P310-P330-P361-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACFFIP180 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACCOTQ063 route compound structure diagram
    ACCOTQ0631415928-75-4In Stock
  4. Then
  5. ACFFIP180 route product structure diagram
    ACFFIP1801346691-35-7
Inquiry

2. ACFFIP180 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACWUMQ286 route compound structure diagram
    ACWUMQ28696-35-5In Stock
  2. Plus
  3. ACENAW254 route compound structure diagram
    ACENAW2541837-55-4In Stock
  4. Then
  5. ACFFIP180 route product structure diagram
    ACFFIP1801346691-35-7
Inquiry

3. ACFFIP180 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACWUMQ286 route compound structure diagram
    ACWUMQ28696-35-5In Stock
  2. Plus
  3. ACCOTQ063 route compound structure diagram
    ACCOTQ0631415928-75-4In Stock
  4. Then
  5. ACFFIP180 route product structure diagram
    ACFFIP1801346691-35-7
Inquiry

Comments (0)